← All stocks

MADRIGAL PHARMACEUTICALS, INC.

MDGL Net selling
CIK 0001157601 #854 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$6.58M
$6.24M on a plan · $0.00 straight out of an exercise
Sold at will
$341.94K
1 of 25 sales
Net
−$6.58M
−$341.94K against sales at will

By person

17 insiders · 25 transactions
117×

Bill Sibold holds 117 times base salary in stock. $108.04M of shares against $918.53K in salary for 2025.

Salary from the company's own proxy. The shares are what Bill Sibold last reported holding, valued at $546.38, the price Common Stock was last bought or sold at on the open market here, on 11 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Sibold William John
President and CEO
$6.24M (24) scheduled
−$6.24M
197,746
0.8559%
$108.04M
+253.8%
Kelley Shannon T
General Counsel
$341.94K (1)
−$341.94K
11,474
0.0497%
$6.27M
+43.7%
BAKER BROS. ADVISORS LP entity
Director
1,948,876
8.44%
$1.06B
+9.6%
Taub Rebecca
Director
452,667
1.96%
$247.33M
−1.4%
CRAVES FRED B
Director
361,076
1.56%
$197.28M
−1.9%
FRIEDMAN PAUL A
Director
187,164
0.8101%
$102.26M
+0.4%
Levy Richard S
Director
22,469
0.0973%
$12.28M
+104.0%
Huntsman Carole
Chief Commercial Officer
12,692
0.0549%
$6.93M
+10.6%
Dier Mardi
EVP and CFO
12,490
0.0541%
$6.82M
+40.7%
Soergel David
Chief Medical Officer
10,033
0.0434%
$5.48M
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
5,789
0.0251%
$3.16M
+5.3%
Daly James M
Director
3,081
0.0133%
$1.68M
+61.1%
BATE KENNETH
Director
2,627
0.0114%
$1.44M
+37.4%
Thakkar Rita
Chief Accounting Officer
2,398
0.0104%
$1.31M
FOUSE JACQUALYN A
Director
1,551
0.0067%
$847.43K
Brennan Daniel J.
Director
1,371
0.0059%
$749.08K
REED JOHN C
Director
647
0.0028%
$353.51K
Insider
Date
Role
Action
Shares
Price
Amount
Kelley Shannon T
17 Aug 2026
General Counsel
Sell
664
$514.97
$341.94K

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 24
Sales straight out of an exercise 0
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 0
History held since 24 Oct 2016